Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20552223rdf:typepubmed:Citationlld:pubmed
pubmed-article:20552223lifeskim:mentionsumls-concept:C1516213lld:lifeskim
pubmed-article:20552223lifeskim:mentionsumls-concept:C1556095lld:lifeskim
pubmed-article:20552223lifeskim:mentionsumls-concept:C0034802lld:lifeskim
pubmed-article:20552223lifeskim:mentionsumls-concept:C0007131lld:lifeskim
pubmed-article:20552223lifeskim:mentionsumls-concept:C0026882lld:lifeskim
pubmed-article:20552223lifeskim:mentionsumls-concept:C1122962lld:lifeskim
pubmed-article:20552223lifeskim:mentionsumls-concept:C1135135lld:lifeskim
pubmed-article:20552223lifeskim:mentionsumls-concept:C0015295lld:lifeskim
pubmed-article:20552223pubmed:issue4lld:pubmed
pubmed-article:20552223pubmed:dateCreated2011-3-14lld:pubmed
pubmed-article:20552223pubmed:abstractTextEpidermal growth factor receptor (EGFR) mutations are associated with sensitivity to gefitinib or erlotinib in non-small cell lung cancer (NSCLC). We investigated the relationships between the two most common types of somatic EGFR mutations, exon 19 deletions and L858R mutations, and clinical outcomes of Korean NSCLC patients after treatment with gefitinib or erlotinib.lld:pubmed
pubmed-article:20552223pubmed:languageenglld:pubmed
pubmed-article:20552223pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20552223pubmed:citationSubsetIMlld:pubmed
pubmed-article:20552223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20552223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20552223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20552223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20552223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20552223pubmed:statusMEDLINElld:pubmed
pubmed-article:20552223pubmed:monthAprlld:pubmed
pubmed-article:20552223pubmed:issn1432-1335lld:pubmed
pubmed-article:20552223pubmed:authorpubmed-author:ParkKeunchilKlld:pubmed
pubmed-article:20552223pubmed:authorpubmed-author:KimJung...lld:pubmed
pubmed-article:20552223pubmed:authorpubmed-author:AhnMyung-JuMJlld:pubmed
pubmed-article:20552223pubmed:authorpubmed-author:ChoiYoon-LaYLlld:pubmed
pubmed-article:20552223pubmed:authorpubmed-author:LeeJeeyunJlld:pubmed
pubmed-article:20552223pubmed:authorpubmed-author:ParkYeon...lld:pubmed
pubmed-article:20552223pubmed:authorpubmed-author:SunJong-MuJMlld:pubmed
pubmed-article:20552223pubmed:authorpubmed-author:AhnJin SeokJSlld:pubmed
pubmed-article:20552223pubmed:authorpubmed-author:WonYoung-Woon...lld:pubmed
pubmed-article:20552223pubmed:authorpubmed-author:KimSeung...lld:pubmed
pubmed-article:20552223pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20552223pubmed:volume137lld:pubmed
pubmed-article:20552223pubmed:ownerNLMlld:pubmed
pubmed-article:20552223pubmed:authorsCompleteYlld:pubmed
pubmed-article:20552223pubmed:pagination687-94lld:pubmed
pubmed-article:20552223pubmed:meshHeadingpubmed-meshheading:20552223...lld:pubmed
pubmed-article:20552223pubmed:meshHeadingpubmed-meshheading:20552223...lld:pubmed
pubmed-article:20552223pubmed:meshHeadingpubmed-meshheading:20552223...lld:pubmed
pubmed-article:20552223pubmed:meshHeadingpubmed-meshheading:20552223...lld:pubmed
pubmed-article:20552223pubmed:meshHeadingpubmed-meshheading:20552223...lld:pubmed
pubmed-article:20552223pubmed:meshHeadingpubmed-meshheading:20552223...lld:pubmed
pubmed-article:20552223pubmed:meshHeadingpubmed-meshheading:20552223...lld:pubmed
pubmed-article:20552223pubmed:meshHeadingpubmed-meshheading:20552223...lld:pubmed
pubmed-article:20552223pubmed:meshHeadingpubmed-meshheading:20552223...lld:pubmed
pubmed-article:20552223pubmed:meshHeadingpubmed-meshheading:20552223...lld:pubmed
pubmed-article:20552223pubmed:meshHeadingpubmed-meshheading:20552223...lld:pubmed
pubmed-article:20552223pubmed:meshHeadingpubmed-meshheading:20552223...lld:pubmed
pubmed-article:20552223pubmed:meshHeadingpubmed-meshheading:20552223...lld:pubmed
pubmed-article:20552223pubmed:meshHeadingpubmed-meshheading:20552223...lld:pubmed
pubmed-article:20552223pubmed:meshHeadingpubmed-meshheading:20552223...lld:pubmed
pubmed-article:20552223pubmed:meshHeadingpubmed-meshheading:20552223...lld:pubmed
pubmed-article:20552223pubmed:year2011lld:pubmed
pubmed-article:20552223pubmed:articleTitleThe different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.lld:pubmed
pubmed-article:20552223pubmed:affiliationDivision of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, 50 Irwon-dong Gangnam-gu, Seoul 135-710, Korea.lld:pubmed
pubmed-article:20552223pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:1956entrezgene:pubmedpubmed-article:20552223lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:20552223lld:entrezgene